and the VESPA Study Group M Objectives: Benefits from HAART may be heterogeneous across people living with HIV. We measured the differences in the rate of HAART failure across the various subgroups represented at the level of a country.
Introduction
In the era of HAART, the magnitude of immunological and virological responses to treatment constitute strong predictors of disease progression and death among people living with HIV [1, 2] . The response to HAART has been shown to be influenced by various factors including characteristics at the time of HAART initiation (HIV disease advancement [2] ; history of suboptimal antiviral treatment [3] ), treatment characteristics (HAART duration [4] ; level of adherence [5] ; experience of treatment discontinuation [6] ), sociodemographics (age [7] ; sex [8] ), co-morbidity [depression [9] ; hepatitis C virus (HCV) co-infection [10] ] and ongoing drug use [11] .
In western countries, the HIV-infected population is made up of diverse subgroups characterized by highly contrasted socioeconomic and cultural backgrounds [12] . Longitudinal studies have suggested that after accounting for major established risk factors of treatment failure, benefits from HAART may be heterogeneous across these different subgroups. A lower beneficial impact of HAART on the risk of disease progression or death has been reported among people with a history of injecting drug use (IDU) [4] and among migrants [13] , whereas homosexual men may have benefited from HAART more than others [14] .
Such differences have, however, not been reported consistently across studies. This may be as a result of methodological concerns including the exclusion of some categories of individuals from the study samples, or the inadequate accounting for acknowledged determinants of treatment failure.
The present study aimed at measuring the differences in the rate of failure to HAARTacross the various subgroups of people living with HIV represented at the level of a country, accounting for subgroup differences in major established determinants of response to HAART. We used data from a French national representative sample of people living with HIV and followed at hospital. In France, access to care for HIV infection is universal, and as antiretroviral treatments are provided exclusively through hospital physicians' prescription, HIV infection is almost exclusively managed through hospital outpatient clinics, regardless of disease severity [15] . The sample we used has been constituted specifically with the concern for reflecting the diversity of the HIV epidemic in terms both of individuals' and disease management characteristics, thus allowing us to account for the great heterogeneity in situations encountered at the country level.
Material and methods

Study design
We used data from the ANRS-EN12-VESPA Study, a large survey aimed at studying the social situation and living conditions of people living with HIV in France. The study design has been detailed elsewhere [16] . Data were collected between December 2002 and September 2003 among a random stratified sample of 4963 people with HIV recruited at 102 French hospital departments delivering HIV care. The stratification criteria were the departments' geographical location and size of HIV caseload. Eligible individuals were those diagnosed as being infected with HIV-1 for at least 6 months, aged 18 years or older, and for non-French citizens living in France for at least 6 months. In the participating departments, physicians invited a sample of people living with HIV, randomly selected according to the order in which they were received, to participate in the study. Those with a very poor understanding of the French language were excluded.
Individuals who agreed to participate signed an informed consent and answered a face-to-face standardized questionnaire administered by a trained interviewer, using the Computer Assisted Personal Interview system. Detailed information was collected on individuals' sociodemographic characteristics and on the different aspects of their life with HIV, including access to and use of the healthcare system, health behaviours, occupational status, income, housing, social support, HIV disclosure, HIV-related discriminations, sexual activity and reproductive life. This information concerned both the situation at the time of the study and that at the time of HIV diagnosis; major changes that occurred during the course of the disease were collected, providing retrospective information on participants' social trajectory during the course of the disease. The median length of interview was 40 min. After interview completion, participants received a s15 voucher and were asked to fill in an additional self-administered questionnaire including psychometric scales. Information on health status, including characteristics of HIV infection and its management at the time of the study and retrospectively since diagnosis and HCV serostatus was documented from medical records.
The study reached the ethical requirements of the French Commission nationale de l'informatique et des libertés.
Data collected
Among 4963 eligible individuals, 2932 participants were included in the study. Two hundred and sixty-four were not solicited because of major cognitive impairment or health problems, whereas 1767 declined to participate. Individuals who refused most frequently cited a lack of time; compared with participants they were more likely to have been infected with HIV through a wayother than homo/bisexual contacts and to be employed at the time of the study.
Weighting procedure Non-participation was 41% of the randomized individuals overall, with substantial differences according to HIV transmission category, employment status and immunological status. Major sociodemographic and health-related characteristics were collected both among respondents and non-respondents, allowing for a weighting procedure to take into account this participation bias. This weighting procedure included two steps: first, considering the unequal probability of enrolment related to the heterogeneous frequency of hospital visits, a weight was attributed to each individual corresponding to the inverse number of hospital visits he(she) had S6 AIDS 2007, Vol 21 (suppl 1) reported for the preceding year. Second, to account for non-response, an additional weight was computed, using a method of calibration adjustment [17] , in such a way that the weighted distribution of the participants regarding transmission group, employment status and immunological status was comparable to that of the entire eligible population.
Variables of interest
Different indicators of treatment failure were defined using data from the medical records. Immunological failure was defined as the absence of an increase of 100 CD4 cells/ml or greater between HAART initiation and the time of data collection. Immunovirological failure was defined as the combination of a CD4 cell count of 200 cells/ml or less and a detectable HIV-RNA viral load at the time of data collection. Participants who had developed a first AIDS-defining illness after a period of more than 3 months on HAARTwere considered to be in clinical failure. HAART was defined as the concomitant receipt of at least three antiretroviral agents.
Based on the characteristics of the HIV epidemic in western Europe [12] , participants were divided into seven subgroups corresponding to the most significant groups of people living with HIV infection in France: homo/ bisexual men, IDU heterosexual men, IDU women, French-native heterosexual men without a history of IDU, French-native women without a history of IDU, migrant heterosexual men without a history of IDU, and migrant women without a history of IDU. Non-French natives who did not have French nationality at birth were classified as migrants. These seven subgroups constitute homogeneous epidemiological entities regarding HIV transmission [12] , and show marked differences in socioeconomic characteristics and living conditions [18] .
Data also included information on the following established determinants of response to HAART: (i) data from medical records, i.e. CD4 cell count, HIV-RNA level and AIDS at HAART initiation; time since first HAART initiation and HAART regimen prescribed at the time of data collection; date of HIV diagnosis; and HCV coinfection; (ii) depressive symptoms at the time of interview, as measured by the Hospital Anxiety and Depression Scale [19] included in the self-administered questionnaire; and (iii) participant-reported age and level of treatment adherence at the time of data collection, active drug use in the year preceding interview, and history of interruption of 6 months or more in HIV care since diagnosis. Adherence was assessed using a dichotomous indicator ('highly' versus 'poorly' adherent) validated in previous cohort studies [20] , summarizing four questions dealing with dose taking during the previous week [21] .
Statistical analyses
Analyses were restricted to participants on HAART for at least 6 months at the time of data collection who were antiretroviral naive at the time of HAART initiation. Differences in the frequency of each indicator of treatment failure across the various subgroups were measured using logistic regression models, accounting for weighted data and adjusted for the major established determinants of response to HAART described above. Homo/bisexual men were used as the reference group. All statistical analyses were performed using Stata 9.0 (Stata Corporation, College Station, Texas, USA).
Results
Study population
Overall, 1939 participants had been on HAART for at least 6 months at the time of the study, of whom 896 were antiretroviral naive at HAART initiation. Of these 896, 38.4% were homo/bisexual men, 27.3% were Frenchnative heterosexuals (16.9% men, 10.4% women), 22.3% were migrant heterosexuals (11.0% men, 11.3% women) and 12.0% were IDU (8.7% men, 3.3% women). The majority of the heterosexual migrants originated from sub-Saharan Africa (76.3% of the men and 82.3% of the women).
As shown in Table 1 , these various subgroups showed marked differences on established determinants of response to HAART. Migrant heterosexual women (median age 33 years), were younger than the other groups, whereas French-native heterosexual men were the oldest (median age 47 years). The majority (73.3%) of the IDU participants had been diagnosed as being HIV infected in the pre-HAARTera, whereas this was the case for only one third of the homo/bisexual men and Frenchnative heterosexuals and 13.3% of the migrants. Similarly, individuals with a history of IDU had spent the longest time on HAARTat the time of data collection (57 months in median) and migrants the shortest time (32 months). At the time of data collection, 25.2% of the participants were prescribed a regimen including a protease inhibitor and 46.4% a non-nucleoside reverse transcriptase inhibitor, with no difference across subgroups. At HAART initiation, French-native heterosexual men, IDU and migrants were more likely than homo/bisexual men and French-native heterosexual women to have a marked immunodeficiency (CD4 cell count < 200 cells/ml); French-native heterosexuals men were also more likely to have reached the AIDS stage. Compared with the other subgroups, IDU participants more frequently reported a history of interruption in HIV care (33.8 versus 6.3%) and current drug use at the time of the study (27.2 versus 0.3%); they were also more likely to be HCV co-infected (88.0 versus 6.4%) and to present symptoms of depression (22.1 versus 12.5%). Migrants reported suboptimal adherence more frequently than the other participants in the study (56.1 versus 34.6%).
Differences in treatment failure rates across subgroups Overall, 19.6% of the study participants experienced immunological failure, 3.4% immunovirological failure, and 3.0% clinical failure. As shown in Table 2 , these rates showed substantial variations across the various subgroups: the immunological failure rate ranged from 10.6% among French-native heterosexual men to 37.5% among migrant women; the immunovirological failure rate ranged from 0% among IDU women to 9.2% among IDU men; and the clinical failure rate ranged from 0.6% among French-native heterosexual women to 9.1% among IDU men.
Multivariate analysis accounting for subgroup differences in major established determinants of response to HAART suggested that compared with homo/bisexual men, migrants had higher rates of immunological failure S8 AIDS 2007, Vol 21 (suppl 1) of treatment failure in multivariate analysis included age 50 years or greater, time on HAART less than 24 months, baseline CD4 cell count of 200 cells/ml or less, baseline HIV-RNA level of 100 000 copies/ml or greater, AIDS at baseline, history of interruption in HIV care, suboptimal adherence, HCV co-infection and current drug use.
Discussion
Our results suggest that at the level of a country, here France, long-term benefits from antiretroviral multitherapies are not homogeneous across subgroups of the HIV-infected population. Heterosexual migrants consistently appear to be at increased risk of immunological, immunovirological and clinical treatment failure compared with other people living with HIV, even after accounting for differences in established determinants of response to treatment. Considering that access to care and treatment for HIV infection is universal in France (as reflected in our data by the absence of difference in the type of HAART regimen prescribed across subgroups) and that analyses have taken into account differences in baseline characteristics at HAART initiation, our findings are likely to reflect a heterogeneous response to HAART rather than differences in access to healthcare; the latter, if they exist, may further increase such heterogeneity.
The ANRS-EN12-VESPA Study, with its large randomized sample of people living with HIV and followed at hospital all over France, provides a unique dataset to study the diversity of the HIV-infected population at a national level. The retrospective design of our study has probably allowed for the inclusion of individuals who are likely to be underrepresented in studies assessing treatment outcomes prospectively. Indeed, prospective follow-up is likely to lead to the exclusion of individuals with the most precarious socioeconomic conditions [22] , implying a reduced heterogeneity across individuals with regard to these characteristics in the study sample compared with the diversity existing within the source population. Prospective studies may thus sometimes fail to detect differences across subgroups that are characterized by marked differences in socioeconomic status, and the contribution of other types of studies to the question of inequalities across subgroups appears of importance. Our results suggest that the significant role of major determinants of response to HAARTon treatment failure reported in prospective studies is also found at the population level, and that additional characteristics related to foreign nativity may also play a role beyond that of the established factors.
The interpretation of our results must remain cautious because of concerns related to the retrospective nature of the study. First, people who died between HAART initiation and the study were excluded from the sample. Although this point may have led to an underestimation of treatment failure rates in our study, it is unlikely to have influenced the differences we report because analyses have been adjusted for acknowledged predictors of treatment failure and death. Second, only few points of laboratory measures were available to define immunovirological failure. To ensure accurate indicators of response to treatment despite this limitation, we gave precedence to CD4 cell count measurement rather than HIV-RNA level, which is highly subject to acute changes over time.
Finally, using a single cross-sectional measure of timedependent phenomena such as depressive symptoms, adherence to treatment and ongoing drug use has probably led us to underestimate their association with treatment failure. However, the established predictive role of these factors has been effectively found and accounted for in our analyses. Although information on the different regimens prescribed over time was also lacking, we took into account the duration of HAART treatment as a proxy for this sequencing.
Heterosexual migrants without a history of IDU account for the great majority of the non-French native population living with HIV infection in France (85.4% in our sample), as in other western European countries [12] . They mostly include individuals originating from sub-Saharan Africa (79.3%) or other non-European countries (14.0%), and are characterized by a recent immigration in France (median: 6 years at the time of the study). Non-heterosexual migrants constitute a marginal part of the HIV-infected population (homo/bisexual migrants account for 2.2% of our sample and IDU migrants for 1.6%); moreover, they differ from heterosexual migrants in that they mainly come from other European countries (respectively, 59.4 and 52.7%), and have been settled in France for a long time (respectively, median of 13 and 24 years at the time of the study). For all these reasons, homo/bisexual and IDU migrants have not been analysed as separate subgroups, and have been classified together with French-native homo/bisexuals and IDU, respectively, rather than with heterosexual migrants.
Our finding of an increased risk of treatment failure among heterosexual migrants in France is consistent with data from the Netherlands, suggesting that migrants followed in a clinic in Amsterdam have poorer virological and clinical responses to HAART compared with nonmigrants [13] . On the other hand, migrants were not found to have an impaired response to HAART either in Denmark [23] or in London [24] . The two latter studies included individuals regardless of the history of antiretroviral treatment before HAART initiation; as history of pre-HAART treatment, a strong predictor of response to HAART, is likely to be distributed differentially among migrants and non-migrants, differences may have been underestimated in those studies.
There can be various explanations for our findings. Racial differences in viral subtypes, drug metabolism and levels of CD4 cell count and HIV-RNA level have been shown, with a potential role in the magnitude or the measure of therapeutic response. However, studies have found that race does not constitute an independent predictor of HAART failure [25, 26] , and that immunovirological response to HAART is comparable between people from low and highincome parts of the world [27] , suggesting that racial differences are unlikely to explain our findings.
Alternatively, the heterogeneity we report may result from differences in living conditions and educational/cultural backgrounds. HIV-infected migrants in western countries encounter particularly adverse socioeconomic conditions. Among participants of the ANRS-EN12-VESPA Study, precarious housing conditions and lone parenthood at the time of the study were more frequent among migrants than among French natives [18] . Moreover, over half (53%) of the heterosexual migrants reported financial difficulties, and 33% reported food privation through lack of money in the preceding month, compared with 21 and 7% of the other participants, respectively. Social isolation, as defined by less than weekly contact with family members/friends, concerned 20% of the heterosexual migrants compared with 12% of the others (data available on request). Such adverse living conditions may have indirect effects on response to treatment through various pathways, including poor adherence, high co-morbidity (e.g. depression, tuberculosis, bacterial co-infections), inadequate healthcare, low social support, life event stress, or maladaptive coping [21, [28] [29] [30] [31] . The low level of literacy of HIVinfected migrants [18] may further constitute a barrier to adequate access to care and HIV treatment adherence and knowledge, with consequences on health status [32, 33] . Furthermore, cultural factors as well as the stigmas of HIV, race and ethnicity probably also influence treatment adherence and healthcare providers' attitudes and interactions with their patients [34] . HIV stigmatization in migrant communities may additionally result in low rates of HIV disclosure, with consequent low social support. Among participants of the ANRS-EN12-VESPA Study, 17% of the heterosexual migrants compared with 4% of the others had kept their HIV status secret from their social circle.
Our findings have important public health implications because the proportion of heterosexual migrants coming from countries with high HIV prevalence, especially sub-Saharan Africa, and living in precarious socioeconomic conditions, has been rising drastically in the past few years [12] . Understanding the reasons underlying a poorer response to treatment in this population appears to be important. Although the present study precludes the drawing of any conclusions in terms of causality, our results suggest that living conditions and educational/cultural background may play a major role in therapeutic failure. Further studies should prospectively assess the different pathways involved in such heterogeneity.
